Table 1.
Quintile of baseline serum urate | ||||||
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | All | |
Serum urate (mg/dL) | <4.3 | 4.3–<5.1 | 5.1–<5.8 | 5.8–<6.7 | >=6.7 | |
N. of patients | 177 | 157 | 147 | 169 | 154 | 804 |
Female % | 74.6 | 44.6 | 25.2 | 15.4 | 14.3 | 35.7 |
Age (median) | 57 | 60 | 59 | 61 | 60 | 59 |
BMI | 25.0 | 26.2 | 27.8 | 28.7 | 29.9 | 27.5 |
Current smokers % | 6.2 | 5.1 | 14.3 | 5.3 | 5.2 | 7.1 |
Gout % | 0 | 0.6 | 0.7 | 1.2 | 5.2 | 1.5 |
Hypertension (% use of antihypertensive drugs) | 19.8 | 26.8 | 36.1 | 37.3 | 57.1 | 35.0 |
Thiazides % | 5.7 | 6.4 | 10.2 | 14.2 | 16.2 | 10.4 |
NSAIDs use % | 27.7 | 29.3 | 29.9 | 20.7 | 30.5 | 27.5 |
Endpoint: Yes % | 67.8 | 61.8 | 64.0 | 59.2 | 53.3 | 61.3 |
UPDRS rate of change during follow-up (mean) | 16.9 | 17.0 | 14.8 | 14.1 | 14.3 | 14.9 |
% change in striatal β-CIT uptake (mean) | − 10 | −9 | −10 | −8 | −4 | −8 |